2453 (2453) Fair Value & Analysis

Healthcare · Market cap HK$627M

2 2453 2453 · HK

PriceHK$0.8000

Fair ValueHK$4.51

Upside+463.8%

Quality31/100

Watch 2453 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$3.37 – HK$6.73

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −7.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.7100 – HK$7.10 · fair‑value band HK$3.37 – HK$6.73 · the HK$0.8000 price screens below the HK$4.51 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2453 (2453) currently trades at HK$0.8000, while our model-based Fair Value estimate is HK$4.51 — implying the stock looks roughly 463.8% undervalued today. We read business quality at 31/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Over the trailing twelve months, 2453 generated revenue of HK$460M at a net margin of -55.8%. Revenue grew 53.0% year over year. It earns a return on equity of -15.6%. Net debt stands at HK$2.8B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$460M

Revenue growth (YoY) +53.0%

Net margin -55.8%

Return on equity -15.6%

Free cash flow −HK$260M FY2026

Operating margin -26.4%

More key figures

EPS (TTM) HK$-0.2400

Net debt HK$2.8B FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

2453 reported revenue of HK$448M in FY2026 versus HK$471M in FY2022, a compound −1.2%/yr. Reported net income was −HK$250M in FY2026.

Revenue −1.2%/yr

FY22 HK$471M

FY23 HK$472M

FY24 HK$539M

FY25 HK$388M

FY26 HK$448M

Net income

FY22 −HK$817M

FY23 −HK$541M

FY24 −HK$373M

FY25 −HK$443M

FY26 −HK$250M

Is 2453 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$97.60	R$115.75	+19%
Fresenius SE FSNUY	$11.27	$8.25	-27%
5225 5225	8.70 MYR	2.61 MYR	-70%
IHHHF IHHHF	$1.71	$1.26	-26%
Tenet Healthcare Corporation THC	$178.75	$300.86	+68%
Rede D'Or São Luiz S.A RDOR3	R$33.83	R$46.94	+39%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2453 (2453) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$4.51 versus a price of HK$0.8000 — about +464% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2453?

Our model-based fair value for 2453 is HK$4.51 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.8000.

What is the quality score of 2453?

2453 has a Quality Score of 31/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2453 (2453)?

2453 reported trailing-twelve-month revenue of about HK$460M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2453?

The net profit margin of 2453 is about -55.8%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.